×

Please Remove Adblock
Adverts are the main source of Revenue for DoveMed. Please remove adblock to help us create the best medical content found on the Internet.

Erythroplasia of Queyrat

Last updated June 9, 2017

Approved by: Krish Tangella MD, MBA, FCAP

Middle-aged and elderly men are at risk for the condition. The cause of Squamous Cell Carcinoma In Situ of Penis is unknown, but it is influenced by factors such as HPV infection, poor immunity, high-risk sexual practices, etc.


The topic Erythroplasia of Queyrat you are seeking is a synonym, or alternative name, or is closely related to the medical condition Squamous Cell Carcinoma In Situ of Penis.

Quick Summary:

  • Squamous Cell Carcinoma In Situ of Penis is a malignant condition affecting the skin or mucosal membranes of the penis. The carcinoma may be present as a well-defined red patch; is frequently solitary, but may be many in number
  • The lesion may itch, ulcerate, or even bleed. The condition may be diagnosed definitively through a tissue biopsy
  • Middle-aged and elderly men are at risk for the condition. The cause of Squamous Cell Carcinoma In Situ of Penis is unknown, but it is influenced by factors such as HPV infection, poor immunity, high-risk sexual practices, etc.
  • Any combination of radiation therapy and invasive procedures (surgery) are used to treat Penile Squamous Cell Carcinoma In Situ. The prognosis depends upon early diagnosis and treatment that is administered

Please find comprehensive information on Squamous Cell Carcinoma In Situ of Penis regarding definition, distribution, risk factors, causes, signs & symptoms, diagnosis, complications, treatment, prevention, prognosis, and additional useful information HERE.

What are some Useful Resources for Additional Information onErythroplasia of Queyrat?

American Cancer Society (ACS)
1599 Clifton Road, NE Atlanta, GA 30329-4251
Toll-Free: (800) 227-2345
TTY: (866) 228-4327
Website: http://www.cancer.org 

National Cancer Institute (NCI)
U.S. National Institutes of Health
Public Inquiries Office
Building 31, Room 10A03
31 Center Drive, MSC 8322 Bethesda, MD 20892-2580
Phone: (301) 435-3848
Toll-Free: (800) 422-6237
TTY: (800) 332-8615
Email: cancergovstaff@mail.nih.gov
Website: http://www.cancer.gov

American Academy of Dermatology
930 E. Woodfield Road Schaumburg, IL 60173
Phone: (866) 503-SKIN (7546)
Fax: (847) 240-1859
Website: http://www.aad.org

References and Information Sources used forErythroplasia of Queyrat:

Wolff, K., & Johnson, R. A. (2009). Fitzpatrick's color atlas and synopsis of clinical dermatology. McGraw-Hill Medical.

Thiers, B. H. (1989). Year Book of Dermatology 1988. Archives of Dermatology, 125(8), 1150.

Burns, T., & Breathnach, S. (1992). Rook's Textbook of dermatology Vol 4. London: Blackwell Scientific Publications, 1992.

Bolognia, J. L., Schaffer, J. V., Duncan, K. O., & Ko, C. J. (2014). Dermatology Essentials E-Book. Elsevier Health Sciences.

Helpful Peer-Reviewed Medical Articles forErythroplasia of Queyrat:

Fanning, D. M., & Flood, H. (2012). Erythroplasia of queyrat. Clinics and practice2(3).

Krasagakis, K. (2015). Erythroplasia of Queyrat. In European Handbook of Dermatological Treatments (pp. 303-307). Springer Berlin Heidelberg.

Mose, S. (2013). Erythroplasia de Queyrat. In Encyclopedia of Radiation Oncology (pp. 225-225). Springer Berlin Heidelberg.

Fai, D., Romano, I., Cassano, N., & Vena, G. A. (2012). Methyl-aminolevulinate photodynamic therapy for the treatment of erythroplasia of Queyrat in 23 patients. Journal of Dermatological Treatment23(5), 330-332.

Feldmeyer, L., Krausz-Enderlin, V., Töndury, B., Hafner, J., French, L. E., & Hofbauer, G. F. (2011). Methylaminolaevulinic acid photodynamic therapy in the treatment of erythroplasia of Queyrat. Dermatology223(1), 52-56.

Reviewed and Approved by a member of the DoveMed Editorial Board
First uploaded: June 9, 2017
Last updated: June 9, 2017